Regular ArticleEpidermal Growth Factor Receptor in Vulvar Malignancies and Its Relationship to Metastasis and Patient Survival☆
References (49)
- et al.
Long-term outcome related to epidermal growth factor receptor status in bladder cancer
J Urol
(1995) - et al.
Epidermal growth factor expression in normal ovarian epithelium and ovarian cancer
Am J Obstet Gynecol
(1991) - et al.
Multiparameter flow-cytometric quantitation of epidermal growth factor receptor and c-erB-2 oncoprotein in normal and neoplastic tissues of the female genital tract
Gynecol Oncol
(1991) - et al.
Clinical implications of the epidermal growth factor receptor in the squamous cell carcinoma of the uterine cervix
Gynecol Oncol
(1989) - et al.
Epidermal growth factor expression in normal and malignant endometrium
Am J Obstet Gynecol
(1989) - et al.
Expression of ras oncogene product and EGF receptor in cervical squamous cell carcinomas and its relationship to lymph node involvement
Gynecol Oncol
(1991) - et al.
Epidermal growth factor receptor (EGF-R) expression in non-small cell lung carcinomas correlates with metastatic involvement of hilar and mediastinal lymph nodes in the squamous subtype
Eur J Cancer
(1995) - et al.
Assessment of current International Federation of Gynecology and Obstetrics staging of vulvar carcinoma relative to prognostic factors for survival (a Gynecologic Oncology Group study)
Am J Obstet Gynecol
(1991) - et al.
Sites of failure and times to failure in carcinoma of the vulva treated conservatively: A Gynecologic Oncology Group study
Am J Obstet Gynecol
(1996) - et al.
Papillomavirus, p53 alteration and primary carcinoma of the vulva
Eur J Cancer
(1993)
Prognostic significance of human papilloma virus DNA in vulvar carcinoma
Obstet Gynecol
Assessment of current international federation of gynecology and obstetrics staging of vulvar carcinoma relative to prognostic factors for survival (a GOG Group study)
Am J Obstet Gynecol
Prospective study of the prognostic significance of epidermal growth factor receptor in primary breast cancer
Int J Cancer
Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer
J Clin Oncol
The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival
Br J Cancer
Prognostic utility of epidermal growth factor receptor overexpression in endometrial adenocarcinoma
Cancer
Expression of epidermal growth factor receptor and HER-2/Neu and in normal and neoplastic cervix, vulva, and vagina
Obstet Gynecol
Prognostic value of epidermal growth factor receptor expression in cervical carcinoma
J Clin Pathol
Synergistic inhibitory effect of gamma-interferon and EGF on A431 cells
Anticancer Res
Tissue-specific transformation by oncogenic mutants of epidermal growth factor receptor
Crit Rev Oncogen
Epidermal growth factor receptor expression and the presence of human papillomavirus in cervical squamous intraepithelial lesions
Int J Gynecol Pathol
Epidermal growth factor-related peptides and the epidermal growth factor receptor in normal and malignant prostate
World J Urol
Immunohistochemical study of HER-2/new, epidermal growth factor receptor and steroid receptor expression in normal and malignant endometrium
Obstet Gynecol
Immunohistochemical expression of epidermal growth factor receptor in salivary gland tumours
Virchows Arch A Pathol Anat
Cited by (63)
Molecular events in the pathogenesis of vulvar squamous cell carcinoma
2021, Seminars in Diagnostic PathologyPotential targets for tumor-specific imaging of vulvar squamous cell carcinoma: A systematic review of candidate biomarkers
2020, Gynecologic OncologyCitation Excerpt :Scores were summarized in Table 2. With an expression average of 59% or higher (score > 0): EGFR [11–21], CD44v6 [22–25], GLUT1 [26–28], MRP1 [12,13], MUC1 [29] and CXCR-4 [30] were considered potential candidates for tumor-specific imaging of VSCC. Although VEGF-A [22,27,31] showed an average expression of 45% (score 0), it fulfilled both other criteria and therefore this marker was included as well.
STAT3 signaling mediates tumour resistance to EGFR targeted therapeutics
2017, Molecular and Cellular EndocrinologyCitation Excerpt :Due to its critical regulatory role in many cellular processes, it is no surprise that alterations in EGFR activation including activating mutations and gene amplification (leading to over-expression) has been commonly observed in tumour biopsies compared to normal adjacent tissue. Furthermore, many reports have linked EGFR activation with increased tumour invasiveness and tumour metastatic potential (Neal et al., 1985; Sainsbury et al., 1987; Abbott and Pratt, 1991; Damstrup et al., 1998; Johnson et al., 1997; Khazaie et al., 1993; Parker et al., 1998; Radinsky et al., 1995; Toi et al., 1991). Indeed breast, bladder, ovarian, oesophageal, non-small cell and squamous cell lung carcinoma (NSCLC), colon, head and neck and brain cancers have all been shown to over-express the EGFR (Neal et al., 1985; Sainsbury et al., 1987; Bartlett et al., 1996; Ekstrand et al., 1991; Hendler and Ozanne, 1984; Hollstein et al., 1988; Ishitoya et al., 1989; Libermann et al., 1985; Veale et al., 1987), and this over-expression has often been correlated with poorer overall survival outcomes (Neal et al., 1985; Sainsbury et al., 1987; Bartlett et al., 1996; Veale et al., 1987; Jaros et al., 1992; Mayer et al., 1993).
Identification of molecular targets in vulvar cancers
2017, Gynecologic OncologyNew Therapies in Vulvar Cancer
2017, Translational Advances in Gynecologic CancersThe forgotten woman's cancer: Vulvar squamous cell carcinoma (VSCC) and a targeted approach to therapy
2016, Annals of OncologyCitation Excerpt :As regulators of cellular activity, tyrosine kinase proteins have been investigated for their role in mediating vulvar tumorigenesis and progression. Among tyrosine kinases, C-Kit and epidermal growth factor receptor (EGFR) have been studied most extensively in VSCC [38–45]. The proto-oncogene C-Kit encodes a trans-membrane receptor-type tyrosine kinase that has been implicated in various solid tumors, including lung, breast and testicular cancers [46, 47].
- ☆
M, B. SpornA, B, RobertsD, S, Goodman, eds